JP2009520023A5 - - Google Patents

Download PDF

Info

Publication number
JP2009520023A5
JP2009520023A5 JP2008547181A JP2008547181A JP2009520023A5 JP 2009520023 A5 JP2009520023 A5 JP 2009520023A5 JP 2008547181 A JP2008547181 A JP 2008547181A JP 2008547181 A JP2008547181 A JP 2008547181A JP 2009520023 A5 JP2009520023 A5 JP 2009520023A5
Authority
JP
Japan
Prior art keywords
dopamine
iron
pharmaceutically acceptable
oral administration
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008547181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/050553 external-priority patent/WO2007073325A1/en
Publication of JP2009520023A publication Critical patent/JP2009520023A/ja
Publication of JP2009520023A5 publication Critical patent/JP2009520023A5/ja
Pending legal-status Critical Current

Links

JP2008547181A 2005-12-20 2006-12-06 下肢静止不能症候群を治療及び診断するための方法及び組成物 Pending JP2009520023A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502830 2005-12-20
PCT/SE2006/050553 WO2007073325A1 (en) 2005-12-20 2006-12-06 Method and composition for treating and diagnosing restless legs syndrome

Publications (2)

Publication Number Publication Date
JP2009520023A JP2009520023A (ja) 2009-05-21
JP2009520023A5 true JP2009520023A5 (https=) 2010-01-14

Family

ID=38188943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547181A Pending JP2009520023A (ja) 2005-12-20 2006-12-06 下肢静止不能症候群を治療及び診断するための方法及び組成物

Country Status (11)

Country Link
US (1) US20090304816A1 (https=)
EP (1) EP1973551A1 (https=)
JP (1) JP2009520023A (https=)
KR (1) KR20080078075A (https=)
CN (1) CN101336109A (https=)
AU (1) AU2006327254A1 (https=)
CA (1) CA2634140A1 (https=)
EA (1) EA200801540A1 (https=)
IL (1) IL192325A0 (https=)
WO (1) WO2007073325A1 (https=)
ZA (1) ZA200805358B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
US10617694B2 (en) * 2016-05-11 2020-04-14 Jan Hedner Sultiame for the treatment of sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US6960571B2 (en) * 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
EP1635804B1 (fr) * 2003-05-30 2016-09-21 NLS-1 Pharma AG Utilisation du fer pour le traitement du trouble du deficit de attention/hyper-activite chez les enfants
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa

Similar Documents

Publication Publication Date Title
JP2013542246A5 (https=)
JP2012092127A5 (https=)
JP2012520883A5 (https=)
JP2012512907A5 (https=)
JP2005512995A5 (https=)
JP2010523587A5 (https=)
JP2009538832A5 (https=)
JP2010529118A5 (https=)
RU2011138490A (ru) Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
JP2012255026A5 (https=)
JP2010090168A5 (https=)
JP2014532638A5 (https=)
JP2010529999A5 (https=)
JP2013543482A5 (https=)
JP2008543936A5 (https=)
JP2015044834A5 (https=)
JP2017525712A5 (https=)
Chen et al. Transdermal rotigotine: A clinically innovative dopamine‐receptor agonist for the management of Parkinson's disease
JP2011500658A5 (https=)
JP2009545603A5 (https=)
JP2010518086A5 (https=)
EP3843722B1 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
JP2019517587A5 (https=)
JP2013502446A5 (https=)
JP2007509146A5 (https=)